metformin and Endometrial Neoplasms studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.

Research Excerpts

Excerpt	Relevance	Reference
" The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate."	9.51	Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022)
"For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy."	9.41	Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023)
"This study showed that megestrol plus metformin was significantly better than megestrol alone for the treatment of endometrial hyperplasia without atypia."	9.41	The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. ( Aghajani, R; Arab, M; Ghahghaei-Nezamabadi, A; Khalagi, K; Sadeghi, S; Tehranian, A, 2021)
"To assess the efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrioid endometrial cancer (EEC)."	9.34	Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. ( Chen, XJ; Cheng, YL; Du, Y; Guan, J; Gulinazi, Y; Liu, J; Luo, XZ; Ma, FH; Ning, CC; Shan, WW; Sun, L; Yang, BY; Yu, M; Zhang, HW; Zhu, Q, 2020)
" We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC."	9.22	Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016)
" The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation."	9.19	Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014)
" Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review."	9.12	Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021)
"Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated."	8.90	Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014)
"The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception."	7.91	Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. ( Habu, Y; Ishikawa, H; Kawarai, Y; Kobayashi, T; Mitsuhashi, A; Shozu, M; Usui, H, 2019)
"As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether t can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest."	7.81	Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. ( Li, MX; Li, XM; Wang, H; Zeng, Z; Zhang, Y, 2015)
"The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)."	7.81	The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015)
"Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC."	6.82	The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022)
"Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes."	6.50	Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014)
"Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus."	6.45	Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009)
" The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate."	5.51	Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022)
"For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy."	5.41	Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023)
" The study determined the extent to which LNG-IUD with or without metformin (M) or weight loss (WL) achieves a pathological complete response (pCR) in patients with EAC or EHA."	5.41	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. ( Alizart, M; Armes, JE; Chen, C; Chetty, N; Cummings, M; Eva, L; Garrett, A; Gebski, V; Hoet, G; Janda, M; Land, R; Leung, Y; McNally, O; Nicklin, JL; Obermair, A; Oehler, MK; Perrin, LC; Robledo, KP; Sowden, K; Sykes, P; Tang, A; Tristram, A; Walker, G, 2021)
"This study showed that megestrol plus metformin was significantly better than megestrol alone for the treatment of endometrial hyperplasia without atypia."	5.41	The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. ( Aghajani, R; Arab, M; Ghahghaei-Nezamabadi, A; Khalagi, K; Sadeghi, S; Tehranian, A, 2021)
"Obesity is a significant contributing factor to endometrial cancer risk."	5.39	Chemopreventive effects of metformin on obesity-associated endometrial proliferation. ( Broaddus, RR; Burzawa, JK; Celestino, J; Huang, M; Iglesias, D; Lu, KH; McCampbell, AS; Meyer, LA; Schmandt, R; Urbauer, DL; Yates, MS; Zhang, Q, 2013)
"To assess the efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrioid endometrial cancer (EEC)."	5.34	Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. ( Chen, XJ; Cheng, YL; Du, Y; Guan, J; Gulinazi, Y; Liu, J; Luo, XZ; Ma, FH; Ning, CC; Shan, WW; Sun, L; Yang, BY; Yu, M; Zhang, HW; Zhu, Q, 2020)
" We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC."	5.22	Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016)
"Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95."	5.19	Antiproliferative effect of metformin on the endometrium--a clinical trial. ( Bidadi, S; Foroughi, M; Ghojazadeh, M; Melli, MS; Tabrizi, AD, 2014)
" The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation."	5.19	Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014)
" Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review."	5.12	Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021)
"The aim of the present study was to evaluate the role of metformin in endometrial cancer (EC), focusing on its potential preventive effect in breast cancer and obese patients and its safety and efficacy when added to progesterone monotherapy in EC patients who wish to preserve their fertility."	5.12	The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials. ( Fotiou, A; Iavazzo, C; Lekka, S; Prodromidou, A; Psomiadou, V, 2021)
" Nineteen studies were included, which contained information about the following outcomes: reversal of atypical endometrial hyperplasia, cellular proliferation biomarkers expression and overall survival in metformin-users compared to non-users."	4.95	Effects of metformin on endometrial cancer: Systematic review and meta-analysis. ( Guerra, ENS; Lofrano-Porto, A; Meireles, CG; Pereira, SA; Rêgo, DF; Simeoni, LA; Valadares, LP, 2017)
"Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated."	4.90	Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014)
" Each 10% increase in 1-year adherence to metformin reduced cancer-specific mortality among women with breast cancer (adjusted HR = 0."	4.02	Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. ( Feng, JL; Qin, X, 2021)
"The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception."	3.91	Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. ( Habu, Y; Ishikawa, H; Kawarai, Y; Kobayashi, T; Mitsuhashi, A; Shozu, M; Usui, H, 2019)
"The underlying mechanisms of polycystic ovarian syndrome (PCOS)-induced endometrial dysfunction are not fully understood, and although accumulating evidence shows that the use of metformin has beneficial effects in PCOS patients, the precise regulatory mechanisms of metformin on endometrial function under PCOS conditions have only been partially explored."	3.91	Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, ( Billig, H; Brännström, M; Cui, P; Hu, M; Li, J; Li, X; Shao, LR; Vestin, E; Wang, T; Zhang, J; Zhang, Y, 2019)
"Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited."	3.85	Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested case-control study within Italian healthcare utilization databases. ( Asciutto, R; Bosetti, C; Corrao, G; Franchi, M; La Vecchia, C; Merlino, L; Nicotra, F, 2017)
"As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether t can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest."	3.81	Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. ( Li, MX; Li, XM; Wang, H; Zeng, Z; Zhang, Y, 2015)
"The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)."	3.81	The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015)
"A multi-institutional IRB-approved retrospective cohort analysis was conducted comparing endometrial cancer patients with diabetes mellitus who used metformin (based on medication review at the time of diagnosis) to those who did not use metformin from 2005 to 2010."	3.80	Metformin is associated with improved survival in endometrial cancer. ( Bae-Jump, V; Bolac, C; Clark, L; Franasiak, J; Gehrig, PA; Havrilesky, LJ; Jackson, A; Ko, EM; Moore, DT; Secord, AA; Walter, P, 2014)
"To compare the Ki-67 index of endometrial cancer cells before and after treatment between the metformin and placebo group in women with endometrial cancer (EC)."	2.94	Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial. ( Chotikawichean, N; Insin, P; Petchsila, K; Prueksaritanond, N; Yanaranop, M, 2020)
"In human Ishikawa endometrial cancer cells, MET treatment (60 μM) decreased cell numbers and elicited distinct temporal changes in ESR1, KLF9, PGR, PGR-B, KLF4, DKK1, and other tumor biomarker mRNA levels."	2.94	Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells. ( Alhallak, I; Brown, DM; Burnett, AF; Liu, SJ; Montales, MTE; Pabona, JMP; Quick, CM; Rose, T; Siegel, ER; Simmen, FA; Simmen, RC, 2020)
"Obesity increases risk of endometrial cancer through dysregulation of estrogen and insulin signaling."	2.87	Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. ( Basen-Engquist, K; Broaddus, RR; Coletta, AM; Fellman, B; Levy, E; Lu, K; Medepalli, M; Milbourne, A; Nebgen, D; Schmandt, RE; Soletsky, B; Urbauer, D; Yates, MS; Yuan, Y; Zhang, Q, 2018)
" Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length."	2.82	Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. ( Bosco, M; Braga, A; Cianci, S; Dababou, S; Franchi, MP; Frigerio, M; Gardella, B; Garzon, S; Laganà, AS; Torella, M; Uccella, S; Zorzato, PC, 2022)
"Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC."	2.82	The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022)
"Metformin treatment (median 20 days, range 7-34) was associated with a 17."	2.82	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. ( Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN, 2016)
"Metformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus."	2.82	Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer. ( Cai, D; Feng, M; Qi, Y; Sun, H; Wu, X; Zhao, X, 2016)
"Metformin was administered for a mean of 36."	2.79	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. ( Beauchamp, MC; Drudi, L; Ferenczy, A; Gotlieb, WH; Laskov, I; Pollak, M; Yasmeen, A, 2014)
"Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer."	2.79	Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. ( Kiyokawa, T; Mitsuhashi, A; Sato, Y; Shozu, M, 2014)
"Endometrial hyperplasia was associated with better outcomes."	2.72	Fertility-sparing management for endometrial cancer: review of the literature. ( Bosco, M; Franchi, MP; Garzon, S; Mariani, A; Student, V; Uccella, S; Zorzato, PC, 2021)
"However, data on its effect on endometrial cancer (EC) are unclear."	2.61	Antidiabetic Medications and the Risk of Endometrial Cancer in Patients. ( Liang, Y; Qu, P; Tian, J, 2019)
"Metformin treatment is associated with a significant reduction in OM irrespective of diabetes status in patients with EC."	2.55	Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. ( Gianuzzi, X; Hernandez, AV; Hernandez-Fernandez, W; Palma-Ardiles, G; Pasupuleti, V; Perez-Lopez, FR, 2017)
"Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy."	2.53	Repurposing metformin for cancer treatment: current clinical studies. ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016)
"Metformin is a biguanide drug, typically used for diabetes treatment, currently being studied to evaluate its role in the treatment and prevention of gynecologic cancers."	2.50	Metformin and gynecologic cancers. ( Bae-Jump, V; Stine, JE, 2014)
"Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes."	2.50	Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014)
"Obesity is a known risk factor for many types of cancers and a number of endocrine factors, including adipokines and steroid hormones, are regulated by and regulate AMPK."	2.49	Endocrine-related cancers and the role of AMPK. ( Brown, KA; Samarajeewa, NU; Simpson, ER, 2013)
"Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy."	2.49	New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). ( Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nogami, Y; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Umene, K; Yamagami, W; Yanokura, M, 2013)
"Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing."	2.48	Endometrial carcinoma tumorigenesis and pharmacotherapy research. ( Fang, S; Huang, H; Shu, J; Teichman, PG; Xing, L, 2012)
"Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus."	2.45	Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009)
"Metformin was less effective than the OCP in improving menstrual pattern (Peto odds ratio (OR) 0."	2.44	Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. ( Costello, M; Eden, J; Johnson, N; Shrestha, B; Sjoblom, P, 2007)
"Metformin is a widespread antidiabetic agent that is commonly used as a treatment against type 2 diabetes mellitus patients."	1.91	Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling. ( Dolcet, X; Egea, J; Encinas, M; Matias-Guiu, X; Navaridas, R; Nicholson-Sabaté, N; Perramon-Güell, A; Ruiz-Mitjana, A; Vidal-Sabanés, M; Yeramian, A, 2023)
"Metformin inhibits tumorigenesis in endometrial carcinoma and interferes with the expression of oxidative stress-regulating proteins, such as nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1)."	1.91	Oxidative Stress-regulating Enzymes and Endometrial Cancer Survival in Relation to Metformin Intake in Diabetic Patients. ( Ahtikoski, A; Karihtala, P; Kuusiniemi, E; Puistola, U; Urpilainen, E, 2023)
"We characterized a prospective endometrial carcinoma (EC) cohort containing 138 tumors and 20 enriched normal tissues using 10 different omics platforms."	1.91	Proteogenomic insights suggest druggable pathways in endometrial carcinoma. ( An, E; Anderson, ML; Arend, RC; Bavarva, J; Bu, W; Chen, L; Chinnaiyan, AM; Chu, RK; Czekański, A; Davoli, T; DeLair, D; Demicco, EG; Devereaux, K; Dhanasekaran, SM; Ding, L; Dottino, P; Dou, Y; Dover, B; Fenyö, D; Fillmore, TL; Foxall, M; Gritsenko, MA; Guo, X; Hermann, CE; Hiltke, T; Hong, R; Hostetter, G; Hu, Y; Jędryka, M; Jewell, SD; Johnson, I; Kahn, AG; Katsnelson, L; Kolodziejczak, I; Ku, AT; Kumar-Sinha, C; Kurzawa, P; Lazar, AJ; Lazcano, R; Lei, JT; Li, Y; Liao, Y; Lih, TM; Lin, TT; Liu, T; Liu, W; Lu, RJ; Mani, DR; Martignetti, JA; Masand, RP; Matkowski, R; McKerrow, W; Mesri, M; Monroe, ME; Moon, J; Moore, RJ; Mutch, D; Nestor, MD; Nesvizhskii, AI; Newton, C; Omelchenko, T; Omenn, GS; Payne, SH; Petyuk, VA; Reva, B; Robles, AI; Rodland, KD; Rodriguez, H; Ruggles, KV; Rykunov, D; Savage, SR; Schepmoes, AA; Shi, T; Shi, Z; Smith, RD; Tan, J; Taylor, M; Thiagarajan, M; Tsai, CF; Wang, JM; Wang, P; Wang, YT; Weitz, KK; Wen, B; Williams, CM; Wiznerowicz, M; Wu, Y; Wyczalkowski, MA; Yi, X; Zhang, B; Zhang, H; Zhang, X; Zhao, R, 2023)
"The effect of metformin in breast and endometrial cancer is favourable in the vast majority of studies."	1.72	Metformin in selected malignancies in women. ( Kasprzak, T; Markowska, A; Markowska, J; Stanislawiak-Rudowicz, J; Szarszewska, M, 2022)
"Metformin has been reported to affect cancer cells' metabolism and proliferation mainly through the activation of AMP-activated protein kinase (AMPK)."	1.62	Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism. ( Beguinot, F; Calì, G; Conza, D; Fiory, F; Insabato, L; Mirra, P; Ulianich, L, 2021)
"Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus, especially in obese patients."	1.62	Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line. ( Germeyer, A; Lange, C; Machado Weber, A; Schmidt, R; Schroeder, C; Strowitzki, T, 2021)
"Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D."	1.62	Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. ( Ahtikoski, A; Arima, R; Karihtala, P; Puistola, U; Urpilainen, E, 2021)
" This study sought to identify a predictive and/or pharmacodynamic proteomic signature of metformin response to tailor its pharmacologic use."	1.56	Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. ( Ao, W; Bae-Jump, V; Bateman, NW; Casablanca, Y; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Hope, E; Litzy, T; Maxwell, GL; Oliver, J; Teng, PN; Tommarello, D; Wang, G; Wilson, K; Zhou, M, 2020)
"Metformin can inhibit the proliferation and migration of EC cells by inhibiting the activation of PI3K/AKT/MDM2 signaling pathway."	1.51	Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. ( Chen, LJ; Qiang, P; Shao, Y; Sun, YP; Zhang, J, 2019)
" However, long term use of high dose progestin often lead to progestin resistance."	1.51	Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. ( Chen, X; Feng, Y; Jiang, Y; Wei, Y; Zhang, Z; Zheng, W, 2019)
"RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines were treated with MET and/or SIM."	1.51	Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. ( Kim, JS; Rodriguez, GC; Rosales, R; Thaete, LG; Turbov, J, 2019)
"Metformin treatment significantly activated T cells against Ishikawa and RL95-2 cells."	1.51	Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. ( Li, F; Li, L; Li, N; Li, T; Liu, M; Qin, X; Xue, J, 2019)
"This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility."	1.51	Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. ( Chen, X; Luo, X; Ning, C; Shan, W; Shi, Y; Xie, B; Xie, L; Xu, Y; Yang, B; Zhang, H; Zhu, Q, 2019)
"Metformin has been shown to inhibit EC proliferation; however, its role in early-stage EC and its effects on steroid hormone receptors have not been adequately explored."	1.51	Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. ( Collins, G; DiFeo, A; Mesiano, S, 2019)
"Sixty-five patients diagnosed as endometrial carcinoma were grouped into (n = 33) and non-treatment mixed (n = 32) for analysis."	1.48	Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. ( Cai, D; Feng, M; Sun, H; Wan, Q; Zhao, J; Zhao, X; Zhao, Y, 2018)
"36 arMetformin was recently reported to be a promising agent for the treatment of malignant diseases including EC."	1.48	Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer. ( Chen, Y; Dong, C; Dong, M; Hou, J; Li, L; Mu, N; Qv, L; Wang, Y; Xia, M; Xue, F; Zuo, Y, 2018)
" The secondary analysis evaluated the effect of dosage using a principal components analysis."	1.46	Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. ( Albert, AY; Gill, S; Hutcheon, JA; Kwon, JS, 2017)
"STAT3 is over-expressed in endometrial cancer, and diabetes is a risk factor for the development of type 1 endometrial cancer."	1.46	High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. ( Cohn, DE; Dorayappan, KD; Josyula, S; Riley, MK; Saini, U; Selvendiran, K; Wallbillich, JJ; Wanner, RA; Zingarelli, RA, 2017)
"However, for those patients with type I endometrial cancer, only 1 patient (1."	1.43	Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. ( Burnett, AF; Gehlot, A; Hall, C; Stone, RL; Zorn, KK, 2016)
"Ishikawa endometrial carcinoma cells were cultured for a long period in the presence of the synthetic medroxyprogesterone 17-acetate (MPA) to generate a subline refractory to the growth-suppressive effects of MPA, named Ishikawa/MPA cells."	1.43	[Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance]. ( Niu, YJ; Shi, HR; Xie, Y, 2016)
"In endometriosis and endometrial cancer, LSR was observed not only in the subapical region but also throughout the lateral region as well as in normal endometrial epithelial cells in the secretory phase, and LSR in the cancer was reduced in correlation with the malignancy."	1.43	The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells. ( Hatakeyama, T; Kohno, T; Kojima, T; Konno, T; Saito, T; Satohisa, S; Shimada, H; Takahashi, S; Tsujiwaki, M, 2016)
"Metformin treatment suppressed EC cell growth in a time-dependent manner in vitro; this effect was cancelled by cotreatment with an AMPK inhibitor, compound C."	1.43	Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway. ( Cai, B; Cheng, J; Hong, L; Hu, Y; Huang, J; Huang, T; Li, Z; Luo, C; Wen, T; Yuan, H; Zhang, X; Zhang, Y; Zhu, Y; Zhuang, W; Zou, J, 2016)
"Metformin was not associated with prolonged recurrence-free or cancer-specific survival, irrespective of the patients' body mass index (p=0."	1.43	The prognostic role of metformin in patients with endometrial cancer: a retrospective study. ( Bergmeister, B; Grimm, C; Koelbl, H; Polterauer, S; Reinthaller, A; Seebacher, V, 2016)
"Metformin is a diabetes drug with anticancer properties."	1.42	Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. ( Mitsuhashi, A; Shozu, M; Tsuruoka, N; Uehara, T, 2015)
" The dose-response relationship was demonstrated in various models and an overall reduced risk was consistently supported by sensitivity analyses."	1.42	Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. ( Tseng, CH, 2015)
"Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches."	1.42	Metformin: a modulator of bevacizumab activity in cancer? A case report. ( Aliberti, C; Casarin, A; Indraccolo, S; Nardin, M; Nicoletto, MO; Pomerri, F; Randon, G; Zulato, E, 2015)
"Metformin initiation was associated with a lower risk of endometrial cancer in the unadjusted analysis (HR 0."	1.42	Metformin and the risk of endometrial cancer: a population-based cohort study. ( Bae-Jump, V; Castillo, WC; Funk, MJ; Hong, JL; Ko, EM; Stürmer, T, 2015)
"Metformin could inhibit the proliferation of endometrial cancer cells, the inhibition is associated with the differentiation degree of cancer cells."	1.42	[Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells]. ( Peng, Z; Shi, H; Wang, J; Xie, Y, 2015)
"Metformin could inhibit estrogen-mediated proliferation of human endometrial cancer cells, which might be correlated with its regulation of the expressions of estrogen receptors and estrogen-dependent proliferative genes."	1.40	[Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells]. ( Chen, F; Liu, T; Liu, Y; Xu, H; Yin, Z; Zhang, B; Zhang, J; Zhou, X, 2014)
"Obesity is a significant contributing factor to endometrial cancer risk."	1.39	Chemopreventive effects of metformin on obesity-associated endometrial proliferation. ( Broaddus, RR; Burzawa, JK; Celestino, J; Huang, M; Iglesias, D; Lu, KH; McCampbell, AS; Meyer, LA; Schmandt, R; Urbauer, DL; Yates, MS; Zhang, Q, 2013)
"Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes."	1.39	Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. ( Attias-Geva, Z; Bruchim, I; Fishman, A; Friedman, Y; Sarfstein, R; Werner, H, 2013)
"Metformin is an oral biguanide commonly used for the treatment of type II diabetes and has recently been demonstrated to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers."	1.39	Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. ( Bowser, J; Broaddus, R; Burzawa, J; Celestino, J; Chigurupati, S; Co, NN; Hancock, JF; Iglesias, DA; Lu, KH; Rodkey, TL; Schmandt, R; van der Hoeven, D; Yates, MS; Zhang, Q, 2013)
"Treatment with metformin and paclitaxel resulted in decreased phosphorylation of S6 in both cell lines but only had an additive effect on AMPK phosphorylation in the ECC-1 cell line."	1.38	Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. ( Bae-Jump, VL; Gehrig, PA; Hanna, RK; Malloy, KM; Sun, L; Zhong, Y; Zhou, C, 2012)
"Metformin plays an important role in the inhibition of cancer cell growth and prolongs remission durations."	1.38	Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. ( Dong, L; Duan, T; Feng, Y; Zhang, Z; Zhou, Q; Zhu, Y, 2012)
"The proliferation variety of endometrial cancer cells was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium (MTT) assay after exposure to medroxyprogesterone acetate, metformin, or both reagents; apoptosis rates were assessed by flow cytometry."	1.37	Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. ( Dong, L; Feng, Y; Liu, X; Sui, L; Yang, Y; Yu, Y; Zhang, Z; Zhu, Y, 2011)
"We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin."	1.37	[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. ( Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA, 2011)
"Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression."	1.36	Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. ( Bae-Jump, VL; Cantrell, LA; Gehrig, PA; Malloy, KM; Mendivil, A; Zhou, C, 2010)
"For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction."	1.34	Ovulation induction management of PCOS. ( Guzick, DS, 2007)

Research

Studies (137)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Concentration of Metformin in Adipose Tissue

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (4.38)	29.6817
2010's	91 (66.42)	24.3611
2020's	40 (29.20)	2.80

Authors	Studies
Cobb, LP	1
Siamakpour-Reihani, S	1
Zhang, D	2
Qin, X	3
Owzar, K	1
Zhou, C	3
Conrads, TP	2
Maxwell, GL	2
Darcy, KM	2
Bateman, NW	2
Litzi, T	1
Bae-Jump, V	5
Secord, AA	2
Barczyński, B	1
Frąszczak, K	1
Kotarski, J	1
Chae-Kim, J	1
Garg, G	1
Gavrilova-Jordan, L	1
Blake, LE	1
Kim, TT	1
Wu, Q	1
Hayslip, CC	1
Liu, Y	2
Wang, Y	6
Yao, D	1
Chen, X	5
Zhang, F	1
Feng, Y	7
Li, X	4
Yang, X	1
Cheng, Y	2
Zhou, J	3
Zhang, L	1
Wang, Z	2
Yin, S	1
Zhai, L	1
Huang, T	2
Wu, X	2
Shen, B	1
Dong, Y	1
Zhao, L	1
Chi, Y	1
Jia, Y	1
Wang, J	5
He, Y	1
Dong, X	1
Xiao, H	1
Markowska, A	1
Stanislawiak-Rudowicz, J	1
Kasprzak, T	1
Markowska, J	1
Szarszewska, M	1
Helweg, LP	1
Windmöller, BA	1
Burghardt, L	1
Storm, J	1
Förster, C	1
Wethkamp, N	1
Wilkens, L	1
Kaltschmidt, B	1
Banz-Jansen, C	1
Kaltschmidt, C	1
Gu, W	1
Mitsuhashi, A	9
Kobayashi, T	2
Shozu, M	8
Zeng, X	1
Tan, J	2
Xu, Y	2
Yi, C	1
Uccella, S	2
Zorzato, PC	2
Dababou, S	1
Bosco, M	2
Torella, M	1
Braga, A	1
Frigerio, M	1
Gardella, B	1
Cianci, S	1
Laganà, AS	1
Franchi, MP	2
Garzon, S	2
Imran, M	1
Sachdeva, G	1
Menon, S	1
Das, D	1
Davuluri, S	1
Acharya, K	1
Chaudhari, U	1
Zhao, X	5
Niu, J	1
Shi, C	1
Liu, Z	2
Guan, J	4
Chen, XJ	4
Ushijima, K	2
Tsuda, N	1
Yamagami, W	2
Mikami, M	1
Yaegashi, N	1
Enomoto, T	1
Sun, F	1
Hao, Y	1
Kuang, L	1
Zhang, B	3
Shao, F	1
Li, Y	3
Zhao, Y	2
Dou, Y	1
Katsnelson, L	1
Gritsenko, MA	1
Hu, Y	2
Reva, B	1
Hong, R	1
Wang, YT	1
Kolodziejczak, I	1
Lu, RJ	1
Tsai, CF	1
Bu, W	1
Liu, W	1
Guo, X	1
An, E	1
Arend, RC	1
Bavarva, J	1
Chen, L	1
Chu, RK	1
Czekański, A	1
Davoli, T	1
Demicco, EG	1
DeLair, D	1
Devereaux, K	1
Dhanasekaran, SM	1
Dottino, P	1
Dover, B	1
Fillmore, TL	1
Foxall, M	1
Hermann, CE	1
Hiltke, T	1
Hostetter, G	1
Jędryka, M	1
Jewell, SD	1
Johnson, I	1
Kahn, AG	1
Ku, AT	1
Kumar-Sinha, C	1
Kurzawa, P	1
Lazar, AJ	1
Lazcano, R	1
Lei, JT	1
Liao, Y	1
Lih, TM	1
Lin, TT	1
Martignetti, JA	1
Masand, RP	1
Matkowski, R	1
McKerrow, W	1
Mesri, M	1
Monroe, ME	1
Moon, J	1
Moore, RJ	1
Nestor, MD	1
Newton, C	1
Omelchenko, T	1
Omenn, GS	1
Payne, SH	1
Petyuk, VA	1
Robles, AI	1
Rodriguez, H	1
Ruggles, KV	1
Rykunov, D	1
Savage, SR	1
Schepmoes, AA	1
Shi, T	1
Shi, Z	1
Taylor, M	1
Thiagarajan, M	1
Wang, JM	1
Weitz, KK	1
Wen, B	1
Williams, CM	1
Wu, Y	1
Wyczalkowski, MA	1
Yi, X	2
Zhang, X	2
Zhao, R	1
Mutch, D	1
Chinnaiyan, AM	1
Smith, RD	1
Nesvizhskii, AI	1
Wang, P	1
Wiznerowicz, M	1
Ding, L	1
Mani, DR	1
Zhang, H	3
Anderson, ML	1
Rodland, KD	1
Liu, T	2
Fenyö, D	1
Ruiz-Mitjana, A	1
Vidal-Sabanés, M	1
Navaridas, R	1
Perramon-Güell, A	1
Yeramian, A	1
Nicholson-Sabaté, N	1
Egea, J	1
Encinas, M	1
Matias-Guiu, X	1
Dolcet, X	1
Kuusiniemi, E	1
Karihtala, P	2
Puistola, U	4
Ahtikoski, A	2
Urpilainen, E	3
Habu, Y	1
Kawarai, Y	1
Ishikawa, H	1
Usui, H	1
Karadeniz, Z	1
Aynacıoğlu, AŞ	1
Bilir, A	1
Tuna, MY	1
Teng, PN	1
Hope, E	1
Hood, BL	1
Oliver, J	1
Ao, W	1
Zhou, M	1
Wang, G	1
Tommarello, D	1
Wilson, K	1
Litzy, T	1
Conrads, KA	1
Hamilton, CA	1
Casablanca, Y	1
Sivalingam, VN	2
Latif, A	1
Kitson, S	2
McVey, R	2
Finegan, KG	1
Marshall, K	1
Lisanti, MP	1
Sotgia, F	1
Stratford, IJ	1
Crosbie, EJ	2
Yang, BY	1
Gulinazi, Y	1
Du, Y	1
Ning, CC	1
Cheng, YL	1
Shan, WW	1
Luo, XZ	1
Zhang, HW	1
Zhu, Q	2
Ma, FH	1
Liu, J	1
Sun, L	2
Yu, M	1
Pabona, JMP	1
Burnett, AF	2
Brown, DM	1
Quick, CM	1
Simmen, FA	1
Montales, MTE	1
Liu, SJ	1
Rose, T	1
Alhallak, I	1
Siegel, ER	1
Simmen, RC	1
Zhang, J	5
Zhang, Q	6
Sun, C	1
Huang, Y	2
Wang, Q	1
Acosta-Torres, S	1
Murdock, T	1
Matsuno, R	1
Beavis, AL	1
Stone, RL	2
Wethington, SL	1
Levinson, K	1
Grumbine, F	1
Ferriss, JS	1
Tanner, EJ	1
Fader, AN	1
Atiomo, W	3
Kawasaki, Y	1
Hori, M	1
Fujiwara, T	1
Hanaoka, H	2
Petchsila, K	1
Prueksaritanond, N	2
Insin, P	2
Yanaranop, M	1
Chotikawichean, N	1
Tehranian, A	1
Ghahghaei-Nezamabadi, A	1
Arab, M	1
Khalagi, K	1
Aghajani, R	1
Sadeghi, S	1
Gong, H	1
Chen, Y	2
Zhou, D	1
Kyo, S	1
Nakayama, K	1
Student, V	1
Mariani, A	2
Arima, R	3
Lange, C	1
Machado Weber, A	1
Schmidt, R	1
Schroeder, C	1
Strowitzki, T	1
Germeyer, A	1
Janda, M	2
Robledo, KP	1
Gebski, V	2
Armes, JE	1
Alizart, M	1
Cummings, M	1
Chen, C	1
Leung, Y	1
Sykes, P	1
McNally, O	1
Oehler, MK	1
Walker, G	1
Garrett, A	1
Tang, A	1
Land, R	1
Nicklin, JL	1
Chetty, N	1
Perrin, LC	1
Hoet, G	1
Sowden, K	1
Eva, L	1
Tristram, A	1
Obermair, A	2
Feng, JL	1
Conza, D	1
Mirra, P	1
Calì, G	1
Insabato, L	1
Fiory, F	1
Beguinot, F	1
Ulianich, L	1
Prodromidou, A	1
Lekka, S	1
Fotiou, A	1
Psomiadou, V	1
Iavazzo, C	1
Tang, YL	1
Zhu, LY	1
Yu, J	1
Zeng, XX	1
Hu, KX	1
Liu, JY	1
Xu, JX	1
Perez-Lopez, FR	2
Pasupuleti, V	1
Gianuzzi, X	1
Palma-Ardiles, G	1
Hernandez-Fernandez, W	1
Hernandez, AV	1
Marttila, M	2
Hautakoski, A	2
Arffman, M	2
Sund, R	2
Ilanne-Parikka, P	2
Kangaskokko, J	2
Läärä, E	2
Hinkula, M	2
Meireles, CG	1
Pereira, SA	1
Valadares, LP	1
Rêgo, DF	1
Simeoni, LA	1
Guerra, ENS	1
Lofrano-Porto, A	1
Sun, H	2
Feng, M	2
Zhao, J	1
Wan, Q	1
Cai, D	2
Mu, N	2
Dong, M	1
Li, L	3
Xia, M	1
Qv, L	1
Dong, C	1
Zuo, Y	1
Hou, J	1
Xue, F	2
Hanawa, S	1
Chu, D	1
Wu, J	1
Wang, K	1
Zhao, M	1
Wang, C	1
Guo, R	1
Yates, MS	4
Coletta, AM	1
Schmandt, RE	1
Medepalli, M	1
Nebgen, D	1
Soletsky, B	1
Milbourne, A	1
Levy, E	1
Fellman, B	1
Urbauer, D	1
Yuan, Y	1
Broaddus, RR	4
Basen-Engquist, K	1
Lu, K	1
Collins, G	1
Mesiano, S	1
DiFeo, A	1
Bai, M	1
Yang, L	1
Liao, H	2
Liang, X	1
Xie, B	2
Xiong, J	1
Tao, X	1
Zhang, Z	6
Zheng, W	3
Wang, XH	1
Zhang, Y	5
Liu, LZ	1
Shang, CG	1
Scheen, AJ	1
Philips, JC	1
Kridelka, F	1
Yang, B	1
Xie, L	1
Shan, W	1
Ning, C	1
Shi, Y	1
Luo, X	1
Wang, T	1
Hu, M	1
Cui, P	1
Li, J	1
Vestin, E	1
Brännström, M	1
Shao, LR	1
Billig, H	2
Tian, J	1
Liang, Y	1
Qu, P	1
Qiang, P	1
Shao, Y	1
Sun, YP	1
Chen, LJ	1
Jiang, Y	1
Wei, Y	1
Kim, JS	1
Turbov, J	1
Rosales, R	1
Thaete, LG	1
Rodriguez, GC	1
Cao, C	1
Zhou, JY	1
Xie, SW	1
Guo, XJ	1
Li, GT	1
Gong, YJ	1
Yang, WJ	1
Li, Z	2
Zhong, RH	1
Shao, HH	1
Zhu, Y	5
Xue, J	1
Li, N	1
Li, F	1
Li, T	1
Liu, M	1
Celestino, J	3
Schmandt, R	4
McCampbell, AS	1
Urbauer, DL	2
Meyer, LA	1
Burzawa, JK	1
Huang, M	1
Iglesias, D	2
Lu, KH	4
Becker, C	1
Jick, SS	1
Meier, CR	1
Bodmer, M	1
Sarfstein, R	1
Friedman, Y	1
Attias-Geva, Z	1
Fishman, A	1
Bruchim, I	1
Werner, H	1
Iglesias, DA	1
van der Hoeven, D	1
Rodkey, TL	1
Co, NN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268]	Phase 2	104 participants (Anticipated)	Interventional	2022-03-11	Recruiting
Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer[NCT01911247]	Early Phase 1	28 participants (Actual)	Interventional	2011-05-31	Completed
A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium[NCT01686126]	Phase 2	165 participants (Actual)	Interventional	2012-12-31	Active, not recruiting
Endometrial Cancer Recurrence in Patients Taking Metformin[NCT05192850]		100 participants (Anticipated)	Observational	2021-12-27	Active, not recruiting
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)[NCT03257228]		24 participants (Actual)	Observational	2014-11-01	Completed
The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.[NCT04385667]	Phase 2/Phase 3	143 participants (Actual)	Interventional	2020-05-20	Completed
Metformin Pharmacology in Human Cancers[NCT03477162]	Early Phase 1	18 participants (Actual)	Interventional	2018-05-15	Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.)
An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients[NCT04212377]	Phase 2	8 participants (Actual)	Interventional	2019-04-08	Completed
Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309]		30 participants (Actual)	Interventional	2021-09-01	Completed
Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882]	Phase 3	188 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471]		45 participants (Anticipated)	Observational	2021-06-30	Not yet recruiting
Pilot Study on the Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic[NCT05196568]		100 participants (Anticipated)	Interventional	2021-07-01	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Plasma.

Intervention	ng/g (Median)
Metformin	70

To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Tumor-adjacent Normal Tissue

Intervention	ng/mL (Median)
Metformin	450

To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Whole Blood.

Intervention	ng/g (Median)
Metformin	749

To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery

Lung Tumor Tissue Concentration of Metformin

Intervention	ng/mL (Median)
Metformin	514

To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery

Article	Year
Perspectives of metformin use in endometrial cancer and other gynaecological malignancies. Journal of drug targeting, 2022, Volume: 30, Issue:4 Topics: Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Hypogly	2022
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasm	2021
Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links. Medicine, 2022, Aug-26, Volume: 101, Issue:34 Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Ag	2022
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas, Lithuania), 2022, Sep-11, Volume: 58, Issue:9 Topics: Conservative Treatment; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservati	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Frontiers in endocrinology, 2022, Volume: 13 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2022
Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. Frontiers in endocrinology, 2023, Volume: 14 Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Metformin; N	2023
New therapeutic approaches for the fertility-sparing treatment of endometrial cancer. The journal of obstetrics and gynaecology research, 2020, Volume: 46, Issue:2 Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Orga	2020
Prognostic significance of metformin treatment in endometrial cancer: a meta-analysis. Die Pharmazie, 2020, 08-01, Volume: 75, Issue:8 Topics: Diabetes Mellitus; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Prognosis	2020
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies. International journal of molecular sciences, 2020, Aug-23, Volume: 21, Issue:17 Topics: Diabetes Complications; Drug Resistance, Neoplasm; Endometrial Neoplasms; Estrogens; Female; Glucose	2020
Fertility-sparing management for endometrial cancer: review of the literature. Minerva medica, 2021, Volume: 112, Issue:1 Topics: Administration, Oral; Drug Carriers; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertili	2021
The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials. Journal of gynecology obstetrics and human reproduction, 2021, Volume: 50, Issue:9 Topics: Breast Neoplasms; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hypoglycemic Agents	2021
Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis. BioMed research international, 2017, Volume: 2017 Topics: Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Pr	2017
Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas, 2017, Volume: 101 Topics: Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Re	2017
Effects of metformin on endometrial cancer: Systematic review and meta-analysis. Gynecologic oncology, 2017, Volume: 147, Issue:1 Topics: Biomarkers, Tumor; Chemotherapy, Adjuvant; Endometrial Hyperplasia; Endometrial Neoplasms; Endometri	2017
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC cancer, 2018, 04-18, Volume: 18, Issue:1 Topics: Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Recurrence, Local; O	2018
[Role of metformin in gynaecology and obstetrics]. Revue medicale de Liege, 2018, Volume: 73, Issue:12 Topics: Breast Neoplasms; Diabetes, Gestational; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents;	2018
Antidiabetic Medications and the Risk of Endometrial Cancer in Patients. Gynecologic and obstetric investigation, 2019, Volume: 84, Issue:5 Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic	2019
Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecologic oncology, 2014, Volume: 132, Issue:1 Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Metformin; Polycystic Ovary Syndrome	2014
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8 Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Diabetes Complications; Endometrial N	2014
Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. Journal of experimental & clinical cancer research : CR, 2014, May-11, Volume: 33 Topics: Animals; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Endometrium; Female; Humans; Metfo	2014
Metformin and gynecologic cancers. Obstetrical & gynecological survey, 2014, Volume: 69, Issue:8 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hu	2014
Repurposing metformin for cancer treatment: current clinical studies. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho	2016
Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. European journal of cancer (Oxford, England : 1990), 2016, Volume: 59 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Endometrial Neop	2016
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. Critical reviews in oncology/hematology, 2016, Volume: 105 Topics: Animals; Breast Neoplasms; Drug Repositioning; Endometrial Neoplasms; Female; Humans; Metformin; Ova	2016
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine reviews, 2009, Volume: 30, Issue:1 Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F	2009
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine reviews, 2009, Volume: 30, Issue:1 Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F	2009
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine reviews, 2009, Volume: 30, Issue:1 Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F	2009
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine reviews, 2009, Volume: 30, Issue:1 Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F	2009
Endometrial carcinoma tumorigenesis and pharmacotherapy research. Minerva endocrinologica, 2012, Volume: 37, Issue:2 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Endom	2012
Endocrine-related cancers and the role of AMPK. Molecular and cellular endocrinology, 2013, Feb-25, Volume: 366, Issue:2 Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm	2013
Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:2 Topics: Anticarcinogenic Agents; Carcinoma, Endometrioid; Endometrial Neoplasms; Endometrium; Evidence-Based	2013
New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). Oncology reports, 2013, Volume: 29, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Fe	2013
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Acne Vulgaris; Cardiovascular Diseases; Contraceptives, Oral, Combined; Endometrial Neoplasms; Femal	2007
Polycystic ovary syndrome. Long term sequelae and management. Minerva ginecologica, 2002, Volume: 54, Issue:2 Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag	2002

Article	Year
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr Reproductive health, 2022, Nov-04, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Fema	2022
Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG : an international journal of obstetrics and gynaecology, 2020, Volume: 127, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; China; Drug Therapy, Combination; Endometrial Hy	2020
Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells. Reproductive sciences (Thousand Oaks, Calif.), 2020, Volume: 27, Issue:1 Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Endometrial Neoplasms; Endometrium; Estrogen Recep	2020
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial). BMJ open, 2020, 02-28, Volume: 10, Issue:2 Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Protocols; Disease-Free Survival; Dose-Response Rel	2020
Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial. Asian Pacific journal of cancer prevention : APJCP, 2020, Mar-01, Volume: 21, Issue:3 Topics: Biomarkers; Cell Proliferation; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Metformi	2020
The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. Journal of gynecology obstetrics and human reproduction, 2021, Volume: 50, Issue:6 Topics: Adult; Antineoplastic Agents, Hormonal; Double-Blind Method; Drug Therapy, Combination; Endometrial	2021
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic oncology, 2021, Volume: 161, Issue:1 Topics: Endometrial Neoplasms; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Metformin; M	2021
Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer prevention research (Philadelphia, Pa.), 2018, Volume: 11, Issue:8 Topics: Adiposity; Biomarkers; Body Composition; Body Mass Index; Endometrial Neoplasms; Endometrium; Female	2018
Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer, 2014, Oct-01, Volume: 120, Issue:19 Topics: Adult; Aged; AMP-Activated Protein Kinases; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Wes	2014
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic oncology, 2014, Volume: 134, Issue:3 Topics: Aged; Biomarkers, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Hypoglycemic Age	2014
Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemporary clinical trials, 2014, Volume: 39, Issue:1 Topics: Adenocarcinoma; Biomarkers, Tumor; Diet; Endometrial Neoplasms; Exercise; Female; Humans; Intrauteri	2014
Antiproliferative effect of metformin on the endometrium--a clinical trial. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:23 Topics: Adult; Antineoplastic Agents, Hormonal; Atrophy; Carcinoma, Endometrioid; Endometrial Hyperplasia; E	2014
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:2 Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial	2016
Measuring the biological effect of presurgical metformin treatment in endometrial cancer. British journal of cancer, 2016, Feb-02, Volume: 114, Issue:3 Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia;	2016
Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:9 Topics: Adult; Aged; AMP-Activated Protein Kinases; Carcinoma; Endometrial Neoplasms; Endometrium; Female; H	2016
[Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients]. Voprosy onkologii, 2010, Volume: 56, Issue:6 Topics: Acetylcysteine; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; Colonic Neoplasms; Drug Admi	2010

Article	Year
Obesity and altered angiogenic-related gene expression in endometrial cancer. Gynecologic oncology, 2021, Volume: 163, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Body Mass Index; Calcium-Binding Proteins; Cell Adhesion Mol	2021
Diane-35 and Metformin Induce Autophagy and Apoptosis in Polycystic Ovary Syndrome Women with Early-Stage Endometrial Carcinoma. Genes, 2022, 01-12, Volume: 13, Issue:1 Topics: Androgen Antagonists; Animals; Apoptosis; Autophagy; Cyproterone Acetate; Drug Combinations; Drug Th	2022
Targeting Cancer Metabolism Plasticity with JX06 Nanoparticles via Inhibiting PDK1 Combined with Metformin for Endometrial Cancer Patients with Diabetes. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:8 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus; Disulfiram; Endometrial Neoplasms;	2022
Metformin in selected malignancies in women. Ginekologia polska, 2022, Volume: 93, Issue:5 Topics: Cell Proliferation; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic A	2022
The Diminishment of Novel Endometrial Carcinoma-Derived Stem-like Cells by Targeting Mitochondrial Bioenergetics and MYC. International journal of molecular sciences, 2022, Feb-22, Volume: 23, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell	2022
Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer. BMC cancer, 2022, Jul-11, Volume: 22, Issue:1 Topics: Endometrial Neoplasms; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Medroxyprogeste	2022
Therapeutic metformin concentrations positively regulate proliferation in endometrial epithelial cells via mTOR activation and augmented mitochondrial strength. Canadian journal of physiology and pharmacology, 2023, Jan-01, Volume: 101, Issue:1 Topics: AMP-Activated Protein Kinases; Animals; Cell Proliferation; Endometrial Neoplasms; Epithelial Cells;	2023
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology. Journal of gynecologic oncology, 2023, Volume: 34, Issue:3 Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat	2023
MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:5 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Med	2023
Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer cell, 2023, 09-11, Volume: 41, Issue:9 Topics: beta Catenin; Endometrial Neoplasms; Female; Humans; Metformin; Prospective Studies; Proteogenomics;	2023
Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Diabetes Mellitus, Type 2; Endometrial Neoplasms	2023
Oxidative Stress-regulating Enzymes and Endometrial Cancer Survival in Relation to Metformin Intake in Diabetic Patients. Anticancer research, 2023, Volume: 43, Issue:12 Topics: Cohort Studies; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Kelch-Like ECH-Ass	2023
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. Journal of gynecologic oncology, 2019, Volume: 30, Issue:6 Topics: Adult; Body Mass Index; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; F	2019
Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy. Journal of gynecologic oncology, 2019, Volume: 30, Issue:6 Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Humans; Metformin; Progestins	2019
Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy. Medical hypotheses, 2020, Volume: 134 Topics: Antineoplastic Agents; Cell Division; Cell Physiological Phenomena; Drug Repositioning; Endometrial	2020
Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. Cancer medicine, 2020, Volume: 9, Issue:3 Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Carcinoma, Endometrioid; Cell Cycle Proteins; Cell Line,	2020
Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. British journal of cancer, 2020, Volume: 122, Issue:1 Topics: Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell	2020
Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 125 Topics: ADP-Ribosylation Factors; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Prolifera	2020
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecologic oncology, 2020, Volume: 157, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cohort Studies; Endometria	2020
Is there any move to use metformin for endometrial hyperplasia in routine clinical practice? BJOG : an international journal of obstetrics and gynaecology, 2020, Volume: 127, Issue:7 Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Hypoglycemic Agents; Me	2020
Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. Anticancer research, 2021, Volume: 41, Issue:2 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Finland; Humans;	2021
Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line. PloS one, 2021, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Hyperinsulinism; Hyp	2021
Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. Diabetes research and clinical practice, 2021, Volume: 175 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Data Analysis; Diab	2021
Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism. Cells, 2021, 04-30, Volume: 10, Issue:5 Topics: AMP-Activated Protein Kinase Kinases; Carcinoma; Cell Line, Tumor; Endometrial Neoplasms; Endoplasmi	2021
Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecologic oncology, 2017, Volume: 146, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Case-Control Studies; Diabetes Mellitus, Ty	2017
Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2018, Volume: 34, Issue:5 Topics: Carcinoma; Cell Proliferation; Endometrial Neoplasms; Endometrium; Female; Humans; Metformin; Middle	2018
Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer. Oncology reports, 2018, Volume: 39, Issue:4 Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Drug S	2018
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. PloS one, 2018, Volume: 13, Issue:2 Topics: Adult; Aged; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Metformin; Middle Aged; Protei	2018
Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes Asian Pacific journal of cancer prevention : APJCP, 2018, May-26, Volume: 19, Issue:5 Topics: Adenocarcinoma, Clear Cell; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Diabetes Mellitus, Typ	2018
Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. Reproductive sciences (Thousand Oaks, Calif.), 2019, Volume: 26, Issue:5 Topics: Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endometrial	2019
Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism. Oncogene, 2018, Volume: 37, Issue:42 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epigenesis, Genetic; Female	2018
Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. Anticancer research, 2018, Volume: 38, Issue:7 Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Endometrial Neoplasms;	2018
[Effects of metformin and adiponectin on endometrial cancer cells growth]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2018, Oct-18, Volume: 50, Issue:5 Topics: Adiponectin; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metform	2018
Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecologic oncology, 2019, Volume: 153, Issue:1 Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Prese	2019
Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, International journal of biological sciences, 2019, Volume: 15, Issue:3 Topics: Adult; Apoptosis; Blotting, Western; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Fe	2019
Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. European review for medical and pharmacological sciences, 2019, Volume: 23, Issue:4 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationsh	2019
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 113 Topics: Adenocarcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dr	2019
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecologic oncology, 2019, Volume: 154, Issue:2 Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Drug Therapy, Combination; Endometrial Ne	2019
Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo. International journal of molecular sciences, 2019, Jul-05, Volume: 20, Issue:13 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Protein	2019
Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. European journal of pharmacology, 2019, Sep-15, Volume: 859 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Prolifer	2019
Chemopreventive effects of metformin on obesity-associated endometrial proliferation. American journal of obstetrics and gynecology, 2013, Volume: 209, Issue:1 Topics: Analysis of Variance; Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Endometrial Ne	2013
Metformin and the risk of endometrial cancer: a case-control analysis. Gynecologic oncology, 2013, Volume: 129, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Endometrial Neoplasms; Female; General Practic	2013
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PloS one, 2013, Volume: 8, Issue:4 Topics: Adenylate Kinase; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S	2013
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Molecular cancer therapeutics, 2013, Volume: 12, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplas	2013
Metformin use and endometrial cancer survival. Gynecologic oncology, 2014, Volume: 132, Issue:1 Topics: Aged; Cohort Studies; Diabetes Mellitus; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents;	2014
Metformin is associated with improved survival in endometrial cancer. Gynecologic oncology, 2014, Volume: 132, Issue:2 Topics: Aged; Cohort Studies; Diabetes Mellitus; Disease-Free Survival; Endometrial Neoplasms; Female; Human	2014
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecologic oncology, 2014, Volume: 133, Issue:1 Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Endometrial Hyperplasia; Endom	2014
Metformin treatment and evolution of endometrial cancer. Climacteric : the journal of the International Menopause Society, 2014, Volume: 17, Issue:2 Topics: Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin	2014
Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene, 2015, Jun-04, Volume: 34, Issue:23 Topics: Cell Line, Tumor; Cell Movement; DNA Methylation; Endometrial Neoplasms; Female; Gene Expression Reg	2015
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer medicine, 2015, Volume: 4, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Endometrial Neoplasms; Fe	2015
Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncology reports, 2015, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dru	2015
The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015, Volume: 31, Issue:4 Topics: Adult; Biopsy; Body Mass Index; Cohort Studies; Cyclin D2; Endometrial Neoplasms; Endometrium; Femal	2015
Metformin and the risk of endometrial cancer: a population-based cohort study. Gynecologic oncology, 2015, Volume: 136, Issue:2 Topics: Adult; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Incidence; Metfor	2015
Metformin: a modulator of bevacizumab activity in cancer? A case report. Cancer biology & therapy, 2015, Volume: 16, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Beva	2015
[Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells]. Zhonghua fu chan ke za zhi, 2014, Volume: 49, Issue:12 Topics: Cell Line; Cell Proliferation; Down-Regulation; Endometrial Neoplasms; Endometrium; Estradiol; Estro	2014
Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:1 Topics: Carcinoma; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Female; Humans; Insulin-Like Gr	2015
Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecologic oncology, 2015, Volume: 138, Issue:1 Topics: Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; E	2015
The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. Gynecologic oncology, 2015, Volume: 138, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Endom	2015
Do endometrial cancer patients benefit from metformin intake? Ginekologia polska, 2015, Volume: 86, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endometria	2015
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; China; Endometrial Hyperplasia; Endome	2015
Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Arkansas; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents	2016
The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecologic oncology, 2016, Volume: 140, Issue:2 Topics: Aged; Cohort Studies; Diabetes Mellitus; Disease-Free Survival; Endometrial Neoplasms; Female; Human	2016
[Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells]. Zhonghua fu chan ke za zhi, 2015, Volume: 50, Issue:9 Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Down-Regulation; Endometrial Neopla	2015
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PloS one, 2016, Volume: 11, Issue:1 Topics: Adenocarcinoma, Clear Cell; Aged; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms;	2016
Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells. Oncotarget, 2016, Apr-19, Volume: 7, Issue:16 Topics: Adenocarcinoma; Adult; AMP-Activated Protein Kinases; Apoptosis; Biomarkers, Tumor; Cell Movement; C	2016
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: 20-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Line; Cel	2016
[Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance]. Zhonghua fu chan ke za zhi, 2016, Volume: 51, Issue:2 Topics: Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplast	2016
The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells. Oncotarget, 2016, May-10, Volume: 7, Issue:19 Topics: Adiponectin; Berberine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Endome	2016
Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested case-control study within Italian healthcare utilization databases. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2017, Volume: 26, Issue:3 Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Databases, Factual; Diabetes Mellitus; Endometria	2017
[Diabetes mellitus and endometrial cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74 Suppl 2 Topics: Animals; Diabetes Complications; Diabetes Mellitus; Endometrial Neoplasms; Female; Humans; Hypoglyce	2016
Metformin targeting autophagy overcomes progesterone resistance in endometrial carcinoma. Archives of gynecology and obstetrics, 2016, Volume: 294, Issue:5 Topics: Apoptosis; Autophagy; Cell Cycle; Cell Proliferation; Endometrial Neoplasms; Endometrium; Female; Hu	2016
The prognostic role of metformin in patients with endometrial cancer: a retrospective study. European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 203 Topics: Aged; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metform	2016
Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway. Cancer science, 2016, Volume: 107, Issue:12 Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Disease M	2016
Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Cadherins; Carcinoma; Cell Line, Tumor; Cell Movement; Diabetes Mell	2016
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecologic oncology, 2016, Volume: 143, Issue:3 Topics: Adult; Aged; AMP-Activated Protein Kinases; Apoptosis; Biomarkers, Tumor; Carcinoma, Endometrioid; C	2016
Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:1 Topics: Aged; Case-Control Studies; Diabetes Complications; Diabetes Mellitus; Endometrial Neoplasms; Female	2017
High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. PloS one, 2017, Volume: 12, Issue:1 Topics: Animals; Endometrial Neoplasms; Female; Glucose; Heterografts; Humans; Metformin; Mice; STAT3 Transc	2017
An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. European journal of gynaecological oncology, 2009, Volume: 30, Issue:4 Topics: Adult; Bromocriptine; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Estriol; Female;	2009
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecologic oncology, 2010, Volume: 116, Issue:1 Topics: Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; En	2010
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. The Journal of steroid biochemistry and molecular biology, 2011, Volume: 126, Issue:3-5 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Lin	2011
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:3 Topics: Adult; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cyclic AMP; Cyclic	2011
Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:2 Topics: Apoptosis; Carcinoma, Endometrioid; Down-Regulation; Drug Resistance, Neoplasm; Endometrial Neoplasm	2011
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic oncology, 2012, Volume: 125, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processes; Cell L	2012
Metformin: a potential novel endometrial cancer therapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:2 Topics: Carcinoma, Endometrioid; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Female	2012
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. Voprosy onkologii, 2011, Volume: 57, Issue:6 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ar	2011
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dru	2012
Comment on 'Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'. The journal of obstetrics and gynaecology research, 2013, Volume: 39, Issue:4 Topics: Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Lactoylglutathi	2013
Response to 'Comment on Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'. The journal of obstetrics and gynaecology research, 2013, Volume: 39, Issue:4 Topics: Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Lactoylglutathi	2013
Ovulation induction management of PCOS. Clinical obstetrics and gynecology, 2007, Volume: 50, Issue:1 Topics: Aromatase Inhibitors; Clomiphene; Endometrial Neoplasms; Female; Fertility Agents, Female; Glucocort	2007
Metformin in polycystic ovary syndrome. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Contraceptives, Oral; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Polycys	2008

metformin and Endometrial Neoplasms